Stroke patients with higher body mass index have a poorer prognosis after discharge

Release date: 2007-11-26

Stroke patients with higher body mass index have a poor prognosis after discharge. Ischemic stroke is a cerebrovascular disease in which brain tissue is hypoxic due to blocked or reduced blood flow to the brain. Obesity and overweight are not only important risk factors for the disease, but also may increase the risk of clinical complications, which may affect clinical prognosis. Researchers in Los Angeles recently found that the higher the body mass index, the less likely ischemic stroke patients to go home directly after discharge. Dr. Tannaz Razinia of the UCLA Medical Center in Los Angeles and his colleagues studied the association between body mass index (BMI) and discharge prognosis in 451 patients who were hospitalized for ischemic stroke between 2003 and 2006. . The average age of the patients was 65 years and the males accounted for 28%. Patients were divided into 4 groups according to BMI: BMI ≥ 35 for grade II obesity; 30 ≤ BMI ≤ 34 for grade I obesity; 25 ≤ BMI ≤ 29 for overweight; BMI ≤ 25 for lean. The results showed that there was no significant difference in the number of hospitalization days between the grade I and II obesity groups (6.3 days vs 5.2 days), but the proportion of patients who returned directly after discharge from the class II obesity group was significant. Below the BMI minimum group (26% vs 45%), more patients were discharged to a rehabilitation center, general medical facility or a professional nursing facility for further treatment after discharge. A total of 18 patients died, but no significant differences in in-hospital mortality between the different BMI groups. The researchers point out that the study suggests that obese ischemic stroke patients are not as good as thinner counterparts in terms of discharge prognosis. ——Midi Medical Network

Enrofloxacin belongs to the group of quinolones and acts bactericidal against mainly Gram-negative bacteria like Campylobacter, E. coli, Haemophilus, Mycoplasma, Pasteurella and Salmonella spp.
Enrofloxacin Injection or Enrofloxacin Oral Solution are used in gastrointestinal and respiratory tract infections caused by enrofloxacin sensitive micro-organisms like Campylobacter, E. coli, Haemophilus, Mycoplasma, Pasteurella and Salmonella spp. in calves, cattle, goats, sheep and swine.

Enrofloxacin

Enrofloxacin Injection,Enrofloxacin Oral Solution,Enrofloxacin Injection For Animal,Enrofloxacin Oral Solution For Animal

Hebei Kexing Pharmaceutical Co., Ltd. , https://www.kexingpharma.com